Anna Aulinas1,2,3, Francisco J Guarda1,2,4,5,6, Elaine W Yu2,7, Melanie S Haines1,2, Elisa Asanza1, Lisseth Silva1, Nicholas A Tritos1,2, Joseph Verbalis8, Karen K Miller1,2, Elizabeth A Lawson9,10. 1. Neuroendocrine Unit, Massachusetts General Hospital, Boston, Massachusetts, USA. 2. Harvard Medical School, Boston, Massachusetts, USA. 3. Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER, Unidad 747), ISCIII, Barcelona, Spain. 4. Department of Endocrinology, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile. 5. Center of Translational Endocrinology (CETREN), Pontificia Universidad Católica de Chile, Santiago, Chile. 6. Programa de Tumores Hipofisarios, Red de Salud UC-CHRISTUS, Santiago, Chile. 7. Endocrine Unit, Massachusetts General Hospital, Boston, Massachusetts, USA. 8. Division of Endocrinology and Metabolism, Georgetown University Medical Center, Washington, District of Columbia, USA. 9. Neuroendocrine Unit, Massachusetts General Hospital, Boston, Massachusetts, USA, ealawson@partners.org. 10. Harvard Medical School, Boston, Massachusetts, USA, ealawson@partners.org.
Abstract
INTRODUCTION: Hypopituitary patients are at risk for bone loss. Hypothalamic-posterior pituitary hormones oxytocin and vasopressin are anabolic and catabolic, respectively, to the skeleton. Patients with hypopituitarism may be at risk for oxytocin deficiency. Whether oxytocin and/or vasopressin contribute to impaired bone homeostasis in hypopituitarism is unknown. OBJECTIVES: To determine the relationship between plasma oxytocin and vasopressin levels and bone characteristics (bone mineral density [BMD] and hip structural analysis [HSA]) in patients who have anterior pituitary deficiencies only (APD group) or with central diabetes insipidus (CDI group). METHODS: This is a cross-sectional study. Subjects included 37 men (17 CDI and 20 APD), aged 20-60 years. Main outcome measures were fasting plasma oxytocin and vasopressin levels, and BMD and HSA using dual X-ray absorptiometry. RESULTS: Mean BMD and HSA variables did not differ between the CDI and APD groups. Mean BMD Z-scores at most sites were lower in those participants who had fasting oxytocin levels below, rather than above, the median. There were positive associations between fasting oxytocin levels and (1) BMD Z-scores at the spine, femoral neck, total hip, and subtotal body and (2) favorable hip geometry and strength variables at the intertrochanteric region in CDI, but not APD, participants. No associations between vasopressin levels and bone variables were observed in the CDI or ADP groups. CONCLUSIONS: This study provides evidence for a relationship between oxytocin levels and BMD and estimated hip geometry and strength in hypopituitarism with CDI. Future studies will be important to determine whether oxytocin could be used therapeutically to optimize bone health in patients with hypopituitarism.
INTRODUCTION: Hypopituitary patients are at risk for bone loss. Hypothalamic-posterior pituitary hormones oxytocin and vasopressin are anabolic and catabolic, respectively, to the skeleton. Patients with hypopituitarism may be at risk for oxytocin deficiency. Whether oxytocin and/or vasopressin contribute to impaired bone homeostasis in hypopituitarism is unknown. OBJECTIVES: To determine the relationship between plasma oxytocin and vasopressin levels and bone characteristics (bone mineral density [BMD] and hip structural analysis [HSA]) in patients who have anterior pituitary deficiencies only (APD group) or with central diabetes insipidus (CDI group). METHODS: This is a cross-sectional study. Subjects included 37 men (17 CDI and 20 APD), aged 20-60 years. Main outcome measures were fasting plasma oxytocin and vasopressin levels, and BMD and HSA using dual X-ray absorptiometry. RESULTS: Mean BMD and HSA variables did not differ between the CDI and APD groups. Mean BMD Z-scores at most sites were lower in those participants who had fasting oxytocin levels below, rather than above, the median. There were positive associations between fasting oxytocin levels and (1) BMD Z-scores at the spine, femoral neck, total hip, and subtotal body and (2) favorable hip geometry and strength variables at the intertrochanteric region in CDI, but not APD, participants. No associations between vasopressin levels and bone variables were observed in the CDI or ADP groups. CONCLUSIONS: This study provides evidence for a relationship between oxytocin levels and BMD and estimated hip geometry and strength in hypopituitarism with CDI. Future studies will be important to determine whether oxytocin could be used therapeutically to optimize bone health in patients with hypopituitarism.
Authors: Katherine Neubecker Bachmann; Pouneh K Fazeli; Elizabeth A Lawson; Brian M Russell; Ariana D Riccio; Erinne Meenaghan; Anu V Gerweck; Kamryn Eddy; Tara Holmes; Mark Goldstein; Thomas Weigel; Seda Ebrahimi; Diane Mickley; Suzanne Gleysteen; Miriam A Bredella; Anne Klibanski; Karen K Miller Journal: J Clin Endocrinol Metab Date: 2014-12 Impact factor: 5.958
Authors: L Joseph Melton; Thomas J Beck; Shreyasee Amin; Sundeep Khosla; Sara J Achenbach; Ann L Oberg; B Lawrence Riggs Journal: Osteoporos Int Date: 2005-02-02 Impact factor: 4.507
Authors: Ashwani K Singal; Ramon Bataller; Joseph Ahn; Patrick S Kamath; Vijay H Shah Journal: Am J Gastroenterol Date: 2018-01-16 Impact factor: 10.864
Authors: Jaroslav Rokicki; Tobias Kaufmann; Ann-Marie G de Lange; Dennis van der Meer; Shahram Bahrami; Alina M Sartorius; Unn K Haukvik; Nils Eiel Steen; Emanuel Schwarz; Dan J Stein; Terje Nærland; Ole A Andreassen; Lars T Westlye; Daniel S Quintana Journal: Neuropsychopharmacology Date: 2022-03-28 Impact factor: 8.294
Authors: Clara O Sailer; Bettina Winzeler; Sandrine A Urwyler; Ingeborg Schnyder; Julie Refardt; Anne Eckert; Nimmy Varghese; Martin Fassnacht; Irina Chifu; Elizabeth A Lawson; Joseph G Verbalis; Wiebke Fenske; Mirjam Christ-Crain Journal: Eur J Endocrinol Date: 2021-08-03 Impact factor: 6.558